1:51 PM
 | 
Feb 22, 2019
 |  BioCentury  |  Emerging Company Profile

Gyroscope complements dry AMD

Gyroscope's one-shot dry AMD therapy supplies an upstream complement factor

Gyroscope Therapeutics Ltd.’s complement-targeting gene therapy for dry age-related macular degeneration could have an edge over competing therapies that are dosed chronically or target complement downstream of its key immune mediators.

On Feb. 19, Gyroscope began Phase I/II testing of GT005, an undisclosed complement gene encoded in an adeno-associated viral (AAV) vector and administered via subretinal injection, for dry AMD. Syncona Ltd. launched Gyroscope in 2016 with $34.13 million in seed funding to develop the therapy.

Dry AMD is caused by macular deposits (Drusen deposits) containing complement and other proteins, lipids and cellular debris. There are no therapies approved for the indication and its mechanism is poorly understood. However, genome-wide association studies (GWAS) published in Nature Genetics in 2013 and 2015 identified associations between dry AMD and mutations in...

Read the full 642 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >